ID   S38A2_RAT               Reviewed;         504 AA.
AC   Q9JHE5; Q9JI88;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   29-MAY-2024, entry version 126.
DE   RecName: Full=Sodium-coupled neutral amino acid symporter 2;
DE   AltName: Full=Amino acid transporter A2 {ECO:0000303|PubMed:10747860};
DE   AltName: Full=Solute carrier family 38 member 2;
DE   AltName: Full=System A amino acid transporter 2;
DE   AltName: Full=System A transporter 1 {ECO:0000303|PubMed:10859363};
DE   AltName: Full=System N amino acid transporter 2;
GN   Name=Slc38a2 {ECO:0000312|RGD:69420};
GN   Synonyms=Ata2 {ECO:0000303|PubMed:10747860},
GN   Sa1 {ECO:0000303|PubMed:10859363}, Sat2 {ECO:0000303|PubMed:11311116},
GN   Snat2 {ECO:0000303|PubMed:16629640};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Skeletal muscle;
RX   PubMed=10747860; DOI=10.1074/jbc.c000205200;
RA   Sugawara M., Nakanishi T., Fei Y.-J., Huang W., Ganapathy M.E.,
RA   Leibach F.H., Ganapathy V.;
RT   "Cloning of an amino acid transporter with functional characteristics and
RT   tissue expression pattern identical to that of system A.";
RL   J. Biol. Chem. 275:16473-16477(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Cerebellum;
RX   PubMed=10811809; DOI=10.1074/jbc.m002965200;
RA   Yao D., Mackenzie B., Ming H., Varoqui H., Zhu H., Hediger M.A.,
RA   Erickson J.D.;
RT   "A novel system A isoform mediating Na+/neutral amino acid cotransport.";
RL   J. Biol. Chem. 275:22790-22797(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=10859363; DOI=10.1073/pnas.140152797;
RA   Reimer R.J., Chaudhry F.A., Gray A.T., Edwards R.H.;
RT   "Amino acid transport system A resembles system N in sequence but differs
RT   in mechanism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:7715-7720(2000).
RN   [4]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11311116; DOI=10.1042/bj3550563;
RA   Hyde R., Christie G.R., Litherland G.J., Hajduch E., Taylor P.M.,
RA   Hundal H.S.;
RT   "Subcellular localization and adaptive up-regulation of the system A (SAT2)
RT   amino acid transporter in skeletal-muscle cells and adipocytes.";
RL   Biochem. J. 355:563-568(2001).
RN   [5]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND INDUCTION BY TGFB1.
RX   PubMed=11716780; DOI=10.1042/0264-6021:3600507;
RA   Ensenat D., Hassan S., Reyna S.V., Schafer A.I., Durante W.;
RT   "Transforming growth factor-beta 1 stimulates vascular smooth muscle cell
RT   L-proline transport by inducing system A amino acid transporter 2 (SAT2)
RT   gene expression.";
RL   Biochem. J. 360:507-512(2001).
RN   [6]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.
RX   PubMed=12054432; DOI=10.1016/s0003-9861(02)00006-1;
RA   Freeman T.L., Thiele G.M., Tuma D.J., Machu T.K., Mailliard M.E.;
RT   "ATA2-mediated amino acid uptake following partial hepatectomy is regulated
RT   by redistribution to the plasma membrane.";
RL   Arch. Biochem. Biophys. 400:215-222(2002).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11834730; DOI=10.1074/jbc.m108609200;
RA   Hyde R., Peyrollier K., Hundal H.S.;
RT   "Insulin promotes the cell surface recruitment of the SAT2/ATA2 system A
RT   amino acid transporter from an endosomal compartment in skeletal muscle
RT   cells.";
RL   J. Biol. Chem. 277:13628-13634(2002).
RN   [8]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=11756489; DOI=10.1523/jneurosci.22-01-00062.2002;
RA   Chaudhry F.A., Schmitz D., Reimer R.J., Larsson P., Gray A.T., Nicoll R.,
RA   Kavanaugh M., Edwards R.H.;
RT   "Glutamine uptake by neurons: interaction of protons with system a
RT   transporters.";
RL   J. Neurosci. 22:62-72(2002).
RN   [9]
RP   FUNCTION.
RX   PubMed=12021389; DOI=10.1124/mol.61.6.1289;
RA   Takanaga H., Tokuda N., Ohtsuki S., Hosoya K., Terasaki T.;
RT   "ATA2 is predominantly expressed as system A at the blood-brain barrier and
RT   acts as brain-to-blood efflux transport for L-proline.";
RL   Mol. Pharmacol. 61:1289-1296(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15561425; DOI=10.1016/j.neuroscience.2004.09.023;
RA   Gonzalez-Gonzalez I.M., Cubelos B., Gimenez C., Zafra F.;
RT   "Immunohistochemical localization of the amino acid transporter SNAT2 in
RT   the rat brain.";
RL   Neuroscience 130:61-73(2005).
RN   [11]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF HIS-504.
RX   PubMed=16629640; DOI=10.1042/bj20060026;
RA   Baird F.E., Pinilla-Tenas J.J., Ogilvie W.L.J., Ganapathy V., Hundal H.S.,
RA   Taylor P.M.;
RT   "Evidence for allosteric regulation of pH-sensitive System A (SNAT2) and
RT   System N (SNAT5) amino acid transporter activity involving a conserved
RT   histidine residue.";
RL   Biochem. J. 397:369-375(2006).
RN   [12]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16616430; DOI=10.1016/j.neuroscience.2006.02.042;
RA   Melone M., Varoqui H., Erickson J.D., Conti F.;
RT   "Localization of the Na(+)-coupled neutral amino acid transporter 2 in the
RT   cerebral cortex.";
RL   Neuroscience 140:281-292(2006).
RN   [13]
RP   TOPOLOGY, AND INDUCTION.
RX   PubMed=17488712; DOI=10.1074/jbc.m611520200;
RA   Hyde R., Cwiklinski E.L., MacAulay K., Taylor P.M., Hundal H.S.;
RT   "Distinct sensor pathways in the hierarchical control of SNAT2, a putative
RT   amino acid transceptor, by amino acid availability.";
RL   J. Biol. Chem. 282:19788-19798(2007).
RN   [14]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SODIUM
RP   BINDING, AND MUTAGENESIS OF ASN-82; TYR-337 AND ARG-374.
RX   PubMed=18319257; DOI=10.1074/jbc.m706774200;
RA   Zhang Z., Gameiro A., Grewer C.;
RT   "Highly conserved asparagine 82 controls the interaction of Na+ with the
RT   sodium-coupled neutral amino acid transporter SNAT2.";
RL   J. Biol. Chem. 283:12284-12292(2008).
RN   [15]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INDUCTION.
RX   PubMed=18330498; DOI=10.1007/s00726-008-0050-9;
RA   Kashiwagi H., Yamazaki K., Takekuma Y., Ganapathy V., Sugawara M.;
RT   "Regulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat
RT   skeletal muscle cells by insulin, osmotic shock and amino acid
RT   deprivation.";
RL   Amino Acids 36:219-230(2009).
RN   [16]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SODIUM
RP   BINDING, AND MUTAGENESIS OF THR-384.
RX   PubMed=19589777; DOI=10.1074/jbc.m109.038422;
RA   Zhang Z., Albers T., Fiumera H.L., Gameiro A., Grewer C.;
RT   "A conserved Na(+) binding site of the sodium-coupled neutral amino acid
RT   transporter 2 (SNAT2).";
RL   J. Biol. Chem. 284:25314-25323(2009).
RN   [17]
RP   FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=18832333; DOI=10.1093/cercor/bhn151;
RA   Jenstad M., Quazi A.Z., Zilberter M., Hagleroed C., Berghuis P.,
RA   Saddique N., Goiny M., Buntup D., Davanger S., S Haug F.M., Barnes C.A.,
RA   McNaughton B.L., Ottersen O.P., Storm-Mathisen J., Harkany T.,
RA   Chaudhry F.A.;
RT   "System A transporter SAT2 mediates replenishment of dendritic glutamate
RT   pools controlling retrograde signaling by glutamate.";
RL   Cereb. Cortex 19:1092-1106(2009).
RN   [18]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, AND DOMAIN.
RX   PubMed=21158741; DOI=10.1042/bj20100507;
RA   Zhang Z., Zander C.B., Grewer C.;
RT   "The C-terminal domain of the neutral amino acid transporter SNAT2
RT   regulates transport activity through voltage-dependent processes.";
RL   Biochem. J. 434:287-296(2011).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [20]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, DISULFIDE BOND, AND MUTAGENESIS OF CYS-228; CYS-238; CYS-245;
RP   CYS-279; CYS-303; CYS-401 AND CYS-475.
RX   PubMed=27355203; DOI=10.1371/journal.pone.0158319;
RA   Chen C., Wang J., Cai R., Yuan Y., Guo Z., Grewer C., Zhang Z.;
RT   "Identification of a disulfide bridge in sodium-coupled neutral amino acid
RT   transporter 2(SNAT2) by chemical modification.";
RL   PLoS ONE 11:E0158319-E0158319(2016).
RN   [21]
RP   TOPOLOGY, GLYCOSYLATION AT ASN-254; ASN-258 AND ASN-272, MUTAGENESIS OF
RP   ASN-254; ASN-258 AND ASN-272, AND SUBCELLULAR LOCATION.
RX   PubMed=29678469; DOI=10.1016/j.bbamem.2018.04.005;
RA   Ge Y., Gu Y., Wang J., Zhang Z.;
RT   "Membrane topology of rat sodium-coupled neutral amino acid transporter 2
RT   (SNAT2).";
RL   Biochim. Biophys. Acta 1860:1460-1469(2018).
CC   -!- FUNCTION: Symporter that cotransports neutral amino acids and sodium
CC       ions from the extracellular to the intracellular side of the cell
CC       membrane (PubMed:10747860, PubMed:10811809, PubMed:10859363,
CC       PubMed:11716780, PubMed:11756489, PubMed:12054432, PubMed:16629640,
CC       PubMed:18319257, PubMed:18330498, PubMed:18832333, PubMed:19589777,
CC       PubMed:21158741, PubMed:27355203). The transport is pH-sensitive,
CC       Li(+)-intolerant, electrogenic, driven by the Na(+) electrochemical
CC       gradient and cotransports of neutral amino acids and sodium ions with a
CC       stoichiometry of 1:1 (PubMed:10747860, PubMed:10811809,
CC       PubMed:10859363, PubMed:11716780, PubMed:11756489, PubMed:12054432,
CC       PubMed:16629640, PubMed:18319257, PubMed:19589777, PubMed:21158741).
CC       May function in the transport of amino acids at the blood-brain barrier
CC       (PubMed:12021389). May function in the transport of amino acids in the
CC       supply of maternal nutrients to the fetus through the placenta (By
CC       similarity). Maintains a key metabolic glutamine/glutamate balance
CC       underpinning retrograde signaling by dendritic release of the
CC       neurotransmitter glutamate (PubMed:18832333). Transports L-proline in
CC       differentiating osteoblasts for the efficient synthesis of proline-
CC       enriched proteins and provides proline essential for osteoblast
CC       differentiation and bone formation during bone development (By
CC       similarity). {ECO:0000250|UniProtKB:Q8CFE6,
CC       ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10811809,
CC       ECO:0000269|PubMed:10859363, ECO:0000269|PubMed:11716780,
CC       ECO:0000269|PubMed:11756489, ECO:0000269|PubMed:12021389,
CC       ECO:0000269|PubMed:12054432, ECO:0000269|PubMed:16629640,
CC       ECO:0000269|PubMed:18319257, ECO:0000269|PubMed:18330498,
CC       ECO:0000269|PubMed:18832333, ECO:0000269|PubMed:19589777,
CC       ECO:0000269|PubMed:21158741, ECO:0000269|PubMed:27355203}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-alanine(in) + Na(+)(in) = L-alanine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:29283, ChEBI:CHEBI:29101, ChEBI:CHEBI:57972;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10811809,
CC         ECO:0000269|PubMed:10859363, ECO:0000269|PubMed:11756489,
CC         ECO:0000269|PubMed:18319257, ECO:0000269|PubMed:19589777,
CC         ECO:0000269|PubMed:21158741, ECO:0000269|PubMed:27355203};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:29285;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glycine(in) + Na(+)(in) = glycine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:68228, ChEBI:CHEBI:29101, ChEBI:CHEBI:57305;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10859363};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:68230;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-serine(in) + Na(+)(in) = L-serine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:29575, ChEBI:CHEBI:29101, ChEBI:CHEBI:33384;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10859363,
CC         ECO:0000269|PubMed:16629640};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:29577;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-proline(in) + Na(+)(in) = L-proline(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:28967, ChEBI:CHEBI:29101, ChEBI:CHEBI:60039;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10859363,
CC         ECO:0000269|PubMed:11716780, ECO:0000269|PubMed:11756489};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:28969;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-methionine(in) + Na(+)(in) = L-methionine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:68240, ChEBI:CHEBI:29101, ChEBI:CHEBI:57844;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10859363};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:68242;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-histidine(in) + Na(+)(in) = L-histidine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:71583, ChEBI:CHEBI:29101, ChEBI:CHEBI:57595;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10859363};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:71585;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-asparagine(in) + Na(+)(in) = L-asparagine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:71383, ChEBI:CHEBI:29101, ChEBI:CHEBI:58048;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10859363};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:71385;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-glutamine(in) + Na(+)(in) = L-glutamine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:68236, ChEBI:CHEBI:29101, ChEBI:CHEBI:58359;
CC         Evidence={ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10811809,
CC         ECO:0000269|PubMed:10859363, ECO:0000269|PubMed:11756489,
CC         ECO:0000269|PubMed:18832333};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:68238;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonine(in) + Na(+)(in) = L-threonine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:69999, ChEBI:CHEBI:29101, ChEBI:CHEBI:57926;
CC         Evidence={ECO:0000269|PubMed:10747860};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70001;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-leucine(in) + Na(+)(in) = L-leucine(out) + Na(+)(out);
CC         Xref=Rhea:RHEA:29263, ChEBI:CHEBI:29101, ChEBI:CHEBI:57427;
CC         Evidence={ECO:0000269|PubMed:10747860};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:29265;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-phenylalanine(in) + Na(+)(in) = L-phenylalanine(out) +
CC         Na(+)(out); Xref=Rhea:RHEA:68244, ChEBI:CHEBI:29101,
CC         ChEBI:CHEBI:58095; Evidence={ECO:0000269|PubMed:10747860};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:68246;
CC         Evidence={ECO:0000305|PubMed:10747860};
CC   -!- ACTIVITY REGULATION: Inhibited by N-methyl-D-glucamine
CC       (PubMed:10747860). Inhibited by choline (PubMed:10811809,
CC       PubMed:10859363, PubMed:11716780). Allosteric regulation of sodium ions
CC       binding by pH (PubMed:11756489, PubMed:16629640).
CC       {ECO:0000269|PubMed:10747860, ECO:0000269|PubMed:10811809,
CC       ECO:0000269|PubMed:10859363, ECO:0000269|PubMed:11716780,
CC       ECO:0000269|PubMed:11756489, ECO:0000269|PubMed:16629640}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.529 mM for L-alanine (at pH 7.4) {ECO:0000269|PubMed:10811809};
CC         KM=1.65 mM for L-glutamine (at pH 7.4) {ECO:0000269|PubMed:10811809};
CC         KM=0.94 mM for L-serine (at pH 8.0) {ECO:0000269|PubMed:16629640};
CC         KM=0.23 mM for alpha-(methylamino)isobutyric acid (MeAIB) (at pH 8.0)
CC         {ECO:0000269|PubMed:10747860};
CC         KM=0.14 mM for alpha-(methylamino)isobutyric acid (MeAIB) (at pH 8.0)
CC         {ECO:0000269|PubMed:10859363};
CC         KM=0.53 mM for alpha-(methylamino)isobutyric acid (MeAIB) (at pH 7.4)
CC         {ECO:0000269|PubMed:10811809};
CC         KM=217 uM for L-proline {ECO:0000269|PubMed:11716780};
CC         KM=0.24 mM for alpha-(methylamino)isobutyric acid
CC         {ECO:0000269|PubMed:12054432};
CC         KM=52.2 mM for sodium ion (at pH 7) {ECO:0000269|PubMed:11756489};
CC         KM=11.1 mM for sodium ion (at pH 8) {ECO:0000269|PubMed:11756489};
CC         KM=0.65 mM for alpha-(methylamino)isobutyric acid (MeAIB) (at pH 7)
CC         {ECO:0000269|PubMed:11756489};
CC         KM=0.56 mM for alpha-(methylamino)isobutyric acid (MeAIB) (at pH 8)
CC         {ECO:0000269|PubMed:11756489};
CC         KM=200 uM for L-alanine (with a membrane potential at 0mV)
CC         {ECO:0000269|PubMed:18319257};
CC         KM=120 uM for L-alanine (with a membrane potential at (-)600mV)
CC         {ECO:0000269|PubMed:18319257};
CC         KM=0.8 mM for sodium ion {ECO:0000269|PubMed:19589777};
CC         KM=0.17 mM for alpha-(methylamino)isobutyric acid (MeAIB) (upon
CC         insulin stimulation) {ECO:0000269|PubMed:18330498};
CC         KM=0.08 mM for alpha-(methylamino)isobutyric acid (MeAIB) (upon
CC         osmotic shock) {ECO:0000269|PubMed:18330498};
CC         KM=0.11 mM for alpha-(methylamino)isobutyric acid (MeAIB) (upon Amino
CC         acid deprivation) {ECO:0000269|PubMed:18330498};
CC         KM=175 uM for L-alanine {ECO:0000269|PubMed:21158741};
CC         KM=100 mM for sodium ion {ECO:0000269|PubMed:21158741};
CC         Vmax=142 pmol/min/mg enzyme for L-proline
CC         {ECO:0000269|PubMed:11716780};
CC         Vmax=276 pmol/min/mg enzyme for L-proline (with 10 ng/ml of TGFB1)
CC         {ECO:0000269|PubMed:11716780};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11311116,
CC       ECO:0000269|PubMed:11834730, ECO:0000269|PubMed:12054432,
CC       ECO:0000269|PubMed:15561425, ECO:0000269|PubMed:19589777,
CC       ECO:0000269|PubMed:21158741, ECO:0000269|PubMed:27355203,
CC       ECO:0000269|PubMed:29678469, ECO:0000305|PubMed:10859363}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:17488712,
CC       ECO:0000269|PubMed:29678469}. Note=Insulin promotes recruitment to the
CC       plasma membrane from a pool localized in the trans-Golgi network or
CC       endosomes (PubMed:11834730). Enriched in the somatodendritic
CC       compartment of neurons, it is also detected at the axonal shaft but
CC       excluded from the nerve terminal (PubMed:15561425, PubMed:16616430,
CC       PubMed:18832333). {ECO:0000269|PubMed:11834730,
CC       ECO:0000269|PubMed:15561425, ECO:0000269|PubMed:16616430,
CC       ECO:0000269|PubMed:18832333}.
CC   -!- TISSUE SPECIFICITY: Widely expressed (PubMed:10747860, PubMed:10811809,
CC       PubMed:10859363). Expressed in skeletal muscle and adipose tissue (at
CC       protein level) (PubMed:11311116, PubMed:15561425). Expressed by
CC       glutamatergic and GABAergic neurons together with astrocytes and other
CC       non-neuronal cells in the cerebral cortex (at protein level)
CC       (PubMed:15561425, PubMed:16616430, PubMed:18832333). Widely expressed
CC       in the central nervous systeme where, it is enriched in the spinal cord
CC       and the brainstem nuclei, especially those of the auditory system
CC       (PubMed:15561425). {ECO:0000269|PubMed:10747860,
CC       ECO:0000269|PubMed:10811809, ECO:0000269|PubMed:10859363,
CC       ECO:0000269|PubMed:11311116, ECO:0000269|PubMed:15561425,
CC       ECO:0000269|PubMed:16616430, ECO:0000269|PubMed:18832333}.
CC   -!- INDUCTION: Up-regulation upon amino acid deprivation results from both
CC       increased transcription and protein stabilization (PubMed:11311116,
CC       PubMed:17488712, PubMed:18330498). Up-regulated by TGFB1
CC       (PubMed:11716780). Up-regulation by insulin and osmotic shock
CC       (PubMed:18330498). {ECO:0000269|PubMed:11311116,
CC       ECO:0000269|PubMed:11716780, ECO:0000269|PubMed:17488712,
CC       ECO:0000269|PubMed:18330498}.
CC   -!- DOMAIN: The extracellular C-terminal domain controls the voltage
CC       dependence for amino acid transports activity.
CC       {ECO:0000269|PubMed:21158741}.
CC   -!- PTM: Polyubiquitination by NEDD4L regulates the degradation and the
CC       activity of SLC38A2. {ECO:0000250|UniProtKB:Q8CFE6}.
CC   -!- SIMILARITY: Belongs to the amino acid/polyamine transporter 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF249673; AAF74195.1; -; mRNA.
DR   EMBL; AF173682; AAF75589.2; -; mRNA.
DR   EMBL; AF273024; AAF81796.1; -; mRNA.
DR   RefSeq; NP_851604.1; NM_181090.2.
DR   AlphaFoldDB; Q9JHE5; -.
DR   SMR; Q9JHE5; -.
DR   STRING; 10116.ENSRNOP00000031532; -.
DR   TCDB; 2.A.18.6.4; the amino acid/auxin permease (aaap) family.
DR   GlyCosmos; Q9JHE5; 2 sites, No reported glycans.
DR   GlyGen; Q9JHE5; 3 sites.
DR   iPTMnet; Q9JHE5; -.
DR   PhosphoSitePlus; Q9JHE5; -.
DR   SwissPalm; Q9JHE5; -.
DR   PaxDb; 10116-ENSRNOP00000031532; -.
DR   Ensembl; ENSRNOT00000039002.4; ENSRNOP00000031532.2; ENSRNOG00000006305.6.
DR   Ensembl; ENSRNOT00055021710; ENSRNOP00055017596; ENSRNOG00055012707.
DR   Ensembl; ENSRNOT00060010897; ENSRNOP00060008109; ENSRNOG00060006650.
DR   Ensembl; ENSRNOT00065032133; ENSRNOP00065025645; ENSRNOG00065019116.
DR   GeneID; 29642; -.
DR   KEGG; rno:29642; -.
DR   AGR; RGD:69420; -.
DR   CTD; 54407; -.
DR   RGD; 69420; Slc38a2.
DR   eggNOG; KOG1305; Eukaryota.
DR   GeneTree; ENSGT00940000155486; -.
DR   HOGENOM; CLU_009020_0_1_1; -.
DR   InParanoid; Q9JHE5; -.
DR   OMA; SHYADMD; -.
DR   OrthoDB; 935269at2759; -.
DR   PhylomeDB; Q9JHE5; -.
DR   TreeFam; TF328787; -.
DR   Reactome; R-RNO-210500; Glutamate Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-352230; Amino acid transport across the plasma membrane.
DR   SABIO-RK; Q9JHE5; -.
DR   PRO; PR:Q9JHE5; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000006305; Expressed in esophagus and 19 other cell types or tissues.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005903; C:brush border; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IDA:RGD.
DR   GO; GO:0015172; F:acidic amino acid transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015655; F:alanine:sodium symporter activity; IDA:UniProtKB.
DR   GO; GO:0015171; F:amino acid transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0005283; F:amino acid:sodium symporter activity; IDA:UniProtKB.
DR   GO; GO:0015186; F:L-glutamine transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015194; F:L-serine transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0015175; F:neutral L-amino acid transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0005295; F:neutral L-amino acid:sodium symporter activity; IDA:UniProtKB.
DR   GO; GO:0005298; F:proline:sodium symporter activity; IDA:UniProtKB.
DR   GO; GO:0032328; P:alanine transport; IDA:UniProtKB.
DR   GO; GO:0043090; P:amino acid import; IDA:UniProtKB.
DR   GO; GO:0003333; P:amino acid transmembrane transport; ISO:RGD.
DR   GO; GO:0006865; P:amino acid transport; ISO:RGD.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IEP:RGD.
DR   GO; GO:1903841; P:cellular response to arsenite(3-); ISO:RGD.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0007565; P:female pregnancy; IEP:RGD.
DR   GO; GO:0006868; P:glutamine transport; IDA:ARUK-UCL.
DR   GO; GO:0031460; P:glycine betaine transport; IDA:RGD.
DR   GO; GO:1903803; P:L-glutamine import across plasma membrane; IDA:UniProtKB.
DR   GO; GO:1904271; P:L-proline import across plasma membrane; IDA:UniProtKB.
DR   GO; GO:1903812; P:L-serine import across plasma membrane; IDA:UniProtKB.
DR   GO; GO:0015825; P:L-serine transport; IDA:ARUK-UCL.
DR   GO; GO:0015804; P:neutral amino acid transport; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; ISO:RGD.
DR   GO; GO:0015824; P:proline transport; ISO:RGD.
DR   GO; GO:0080135; P:regulation of cellular response to stress; ISO:RGD.
DR   GO; GO:1903294; P:regulation of glutamate secretion, neurotransmission; IDA:UniProtKB.
DR   GO; GO:0014850; P:response to muscle activity; IEP:RGD.
DR   InterPro; IPR013057; AA_transpt_TM.
DR   PANTHER; PTHR22950; AMINO ACID TRANSPORTER; 1.
DR   PANTHER; PTHR22950:SF207; SODIUM-COUPLED NEUTRAL AMINO ACID TRANSPORTER 2; 1.
DR   Pfam; PF01490; Aa_trans; 1.
PE   1: Evidence at protein level;
KW   Amino-acid transport; Cell membrane; Disulfide bond; Glycoprotein;
KW   Ion transport; Membrane; Phosphoprotein; Reference proteome; Sodium;
KW   Sodium transport; Symport; Transmembrane; Transmembrane helix; Transport;
KW   Ubl conjugation.
FT   CHAIN           1..504
FT                   /note="Sodium-coupled neutral amino acid symporter 2"
FT                   /id="PRO_0000311372"
FT   TOPO_DOM        1..76
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        77..96
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        97..102
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        103..123
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        124..158
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        159..177
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        178..188
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        189..209
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        210..217
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        218..238
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        239..290
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        291..311
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        312..327
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        328..348
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        349..369
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        370..390
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        391..411
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        412..432
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        433..434
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TRANSMEM        435..455
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        456..470
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        471..493
FT                   /note="Helical"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:29678469"
FT   TOPO_DOM        494..504
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:17488712,
FT                   ECO:0000305|PubMed:29678469"
FT   REGION          1..96
FT                   /note="Regulates protein turnover upon amino acid
FT                   deprivation"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         82
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /evidence="ECO:0000305|PubMed:18319257"
FT   BINDING         384
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /evidence="ECO:0000305|PubMed:18319257"
FT   MOD_RES         12
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96QD8"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CFE6"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96QD8"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q96QD8"
FT   CARBOHYD        254
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:29678469"
FT   CARBOHYD        258
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:29678469"
FT   CARBOHYD        272
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:29678469"
FT   DISULFID        245..279
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         82
FT                   /note="N->A: Impairs amino acid transport. Impairs the
FT                   interaction of SNAT2 with the cotransported sodium ion."
FT                   /evidence="ECO:0000269|PubMed:18319257"
FT   MUTAGEN         82
FT                   /note="N->S: Loss of amino acid transport activity. Loss of
FT                   amino acid uptake activity. Reduces the amino acid
FT                   affinity."
FT                   /evidence="ECO:0000269|PubMed:18319257"
FT   MUTAGEN         228
FT                   /note="C->S: Reduces amino acid transport activity of 75%.
FT                   Significantly decreases alanine transport activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         238
FT                   /note="C->S: Decreases alanine transport activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         245
FT                   /note="C->A: Does not affect cell membrane localization."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         245
FT                   /note="C->S: Does not affect amino acid transport activity.
FT                   Significantly decreases alanine transport activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         254
FT                   /note="N->Q: Partially loss of glycosylation. Completely
FT                   loss of glycosylation; when associated with Q-258 and Q-
FT                   272. Decreases expression; when associated with Q-258 and
FT                   Q-272. Does not affect cell membrane localization; when
FT                   associated with Q-258 and Q-272."
FT                   /evidence="ECO:0000269|PubMed:29678469"
FT   MUTAGEN         258
FT                   /note="N->Q: Partially loss of glycosylation. Dramatically
FT                   loss of glycosylation; when associated with Q-272.
FT                   Completely loss of glycosylation; when associated with Q-
FT                   254 and Q-272. Decreases expression; when associated with
FT                   Q-272. Decreases expression; when associated with Q-254 and
FT                   Q-272. Does not affect cell membrane localization; when
FT                   associated with Q-272. Does not affect cell membrane
FT                   localization; when associated with Q-254 and Q-272."
FT                   /evidence="ECO:0000269|PubMed:29678469"
FT   MUTAGEN         272
FT                   /note="N->Q: Partially loss of glycosylation. Dramatically
FT                   loss of glycosylation; when associated with Q-258.
FT                   Completely loss of glycosylation; when associated with Q-
FT                   254 and Q-258. Decreases expression; when associated with
FT                   Q-258. Decreases expression; when associated with Q-254 and
FT                   Q-258. Does not affect cell membrane localization; when
FT                   associated with Q-258. Does not affect cell membrane
FT                   localization; when associated with Q-254 and Q-258."
FT                   /evidence="ECO:0000269|PubMed:29678469"
FT   MUTAGEN         279
FT                   /note="C->A: Does not affect cell membrane localization."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         279
FT                   /note="C->S: Does not affect amino acid transport activity.
FT                   Significantly decreases alanine transport activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         303
FT                   /note="C->S: Reduces amino acid transport activity of 75%.
FT                   Significantly decreases alanine transport activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         337
FT                   /note="Y->A: Impairs transport current. Reduces the amino
FT                   acid affinity."
FT                   /evidence="ECO:0000269|PubMed:18319257"
FT   MUTAGEN         374
FT                   /note="R->Q: Does not affect the alanine-induced transport
FT                   current. Reduces the amino acid affinity."
FT                   /evidence="ECO:0000269|PubMed:18319257"
FT   MUTAGEN         384
FT                   /note="T->A: Does not affect cell membrane localization.
FT                   Eliminates the sodium-induced anion leak current. Inhibits
FT                   amino acid transport activity. Reduces affinity for sodium
FT                   ion."
FT                   /evidence="ECO:0000269|PubMed:19589777"
FT   MUTAGEN         401
FT                   /note="C->S: Does not affect alanine transport activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         475
FT                   /note="C->S: Significantly decreases alanine transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:27355203"
FT   MUTAGEN         504
FT                   /note="H->A: Modifies the transporter pH-sensitivity."
FT                   /evidence="ECO:0000269|PubMed:16629640"
FT   CONFLICT        69
FT                   /note="G -> S (in Ref. 1; AAF74195)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        81
FT                   /note="S -> T (in Ref. 1; AAF74195)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        87
FT                   /note="S -> N (in Ref. 1; AAF74195)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   504 AA;  55554 MW;  F53022C07152648C CRC64;
     MKKTEMGRFN ISPDEDSSSY SSNGDFNYSY PTKQAALKSH YVDVDPENQN FLLESNLGKK
     KYETDFHPGT TSFGMSVFNL SNAIVGSGIL GLSYAMANTG IALFIILLTF VSIFSLYSVH
     LLLKTANEGG SLLYEQLGHK AYGLAGKLAA SGSITMQNIG AMSSYLFIVK YELPLVIKAL
     MNIEDTNGLW YLNGDYLVLL VSFVLILPLS LLRNLGYLGY TSGLSLLCMI FFLIVVICKK
     FQIPCPVEVA LMANETVNGT FTQVALAALA SNSTAADTCR PRYFIFNSQT VYAVPILTFS
     FVCHPAVLPI YEELKSRSRR RMMNVSKISF FAMFLMYLLA ALFGYLTFYE HVESELLHTY
     SAIVGTDILL LVVRLAVLVA VTLTVPVVIF PIRSSVTHLL CPTKEFSWFR HSVITVTILA
     FTNLLVIFVP TIRDIFGFIG ASAAAMLIFI LPSAFYIKLV KKEPMRSVQK IGALCFLLSG
     VVVMIGSMGL IVLDWVHDAS AGGH
//
